US › Healthcare

Editas Medicine Inc (EDIT)

US · Healthcare · Biotechnology

$2.72+0.37%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$11.9M

Revenue YoY

+232.3%

Net profit

$-18.2M

EPS

$-0.15

EPS estimate

$-0.30

Net margin

-153.3%

EPS came in at -0.15 against a street estimate of -0.30 — a beat of 50.0%.

Key statistics

Market cap

$414.7M

Forward P/E

0.0

P/B

3.96

Book value

$0.69

EPS (TTM)

$-0.66

52-week high

$4.54

52-week low

$1.66

50-day MA

$2.99

200-day MA

$2.62

Beta

2.09

Analyst view

Analysts rate Editas Medicine Inc a hold (5 buy, 8 hold, 2 sell out of 15) with an average price target of $6.00.

Shareholding

Insiders

0.18%

Institutions

79.19%

Largest institutional holders

Fund	Stake
TCG Crossover Management, LLC	7.23%
BlackRock Inc	6.03%
Paradigm Biocapital Advisors LP	3.64%
Vanguard Capital Management, LLC	2.74%
Renaissance Technologies Corp	2.59%
Opaleye Management Inc	2.51%
Vivo Capital, LLC	2.31%
Vanguard Portfolio Management, LLC	2.05%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Editas Medicine Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.